Patents by Inventor Ahmad Al-Sabbagh

Ahmad Al-Sabbagh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of autoimmune diseases by oral administration of autoantigens
    Publication number: 20050208061
    Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.
    Type: Application
    Filed: March 25, 2005
    Publication date: September 22, 2005
    Inventors: Howard Weiner, Ariel Miller, Zhengyi Zhang, Ahmad Al-Sabbagh
  • Bystander suppression of autoimmune diseases
    Publication number: 20040115217
    Abstract: This invention pertains to an improvement in the treatment of autoimmune diseases. More specifically, the invention is directed to the use of bystander antigens (i.e. antigens that suppress cells involved in the autoimmune process) for the treatment of autoimmune diseases. The invention also includes pharmaceutical formulations comprising bystander antigens useful in the treatment of autoimmune diseases in mammals.
    Type: Application
    Filed: August 11, 2003
    Publication date: June 17, 2004
    Applicant: Autolmmune Inc.
    Inventors: Howard Weiner, Ariel Miller, Zhengyi Zhang, Ahmad Al-Sabbagh
  • Bystander suppression of type I diabetes by oral administration of glucagon
    Patent number: 6645504
    Abstract: Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 11, 2003
    Assignee: AutoImmune Inc.
    Inventors: Howard Weiner, Ariel Miller, Zhengyi Zhang, Ahmad Al-Sabbagh
  • Suppression of T-cell proliferation using peptide fragments of myelin basic protein
    Patent number: 6036957
    Abstract: Peptides are administered to individuals suffering from multiple sclerosis. The peptides contain immunodominant epitopes of myelin basic protein that are recognized by T-cells from relapsing-remitting multiple sclerosis patients, and that are contained in the 84-102 and 143-168 regions of human MBP.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 14, 2000
    Assignee: Autoimmune, Inc.
    Inventors: Howard L. Weiner, David A. Hafler, Ariel Miller, Ahmad Al-Sabbagh
  • Treatment of autoimmune disease using tolerization in combination with methotrexate
    Patent number: 5935577
    Abstract: A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: August 10, 1999
    Assignee: Autoimmune Inc.
    Inventors: Howard L. Weiner, Ahmad Al-Sabbagh, Patricia A. Nelson
  • Peptide fragments of myelin basic protein
    Patent number: 5858980
    Abstract: Peptides ate provided that are related to immunodominant regions of human MBP.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 12, 1999
    Assignee: Autoimmune, Inc.
    Inventors: Howard L. Weiner, David A. Hafler, Ariel Miller, Ahmad Al-Sabbagh